Literature DB >> 8894186

Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs.

P S Pagel1, D A Hettrick, D C Warltier.   

Abstract

1. The distribution of cardiac output during administration of levosimendan, a new myofilament calcium sensitizer, is unknown. We examined and compared the effects of levosimendan, pimobendan, and milrinone on regional tissue perfusion by use of the radioactive microsphere technique in barbiturate-anaesthetized dogs. 2. Haemodynamics and regional blood flow were determined before and during infusions of levosimendan (0.75, 1.5, and 3.0 micrograms kg-1 min-1), pimobendan (10, 20, and 40 micrograms kg-1 min-1), or milrinone (1.0, 2.0, and 4.0 micrograms kg-1 min-1). 3. All three drugs caused similar increases in heart rate, cardiac output, and left ventricular +dP/dt and decreases in end-diastolic pressure and systemic vascular resistance. No changes in subendocardial, midmyocardial, and subepicardial blood flow occurred during administration of levosimendan. However, a redistribution of blood flow from subendocardium to subepicardium was observed. Pimobendan increased midmyocardial and subepicardial blood flow and reduced the endo/epi ratio to a greater degree than levosimendan. Milrinone did not affect myocardial perfusion. 4. Levosimendan increased blood flow to the renal medulla and decreased renal medullary and cortical vascular resistance. Levosimendan increased blood flow to the small intestine and liver and reduced vascular resistance in these organs. Pimobendan increased hepatic blood flow to a greater degree than levosimendan but did not alter small intestinal perfusion. All three drugs decreased splenic blood flow to similar degrees. Levosimendan and pimobendan reduced cerebral vascular resistance. Levosimendan and milrinone reduced skeletal muscle vascular resistance. 5. The results indicate that levosimendan, pimobendan, and milrinone cause subtlety different alterations in regional tissue perfusion while producing similar haemodynamic effects.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8894186      PMCID: PMC1915696          DOI: 10.1111/j.1476-5381.1996.tb15716.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  33 in total

1.  Dose-range study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction.

Authors:  J Lilleberg; S Sundberg; M S Nieminen
Journal:  J Cardiovasc Pharmacol       Date:  1995       Impact factor: 3.105

2.  Total and regional coronary blood flow measured by radioactive microspheres in conscious and anesthetized dogs.

Authors:  R J Domenech; J I Hoffman; M I Noble; K B Saunders; J R Henson; S Subijanto
Journal:  Circ Res       Date:  1969-11       Impact factor: 17.367

Review 3.  New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 1.

Authors:  W S Colucci; R F Wright; E Braunwald
Journal:  N Engl J Med       Date:  1986-01-30       Impact factor: 91.245

4.  Effects of AR-L 115 BS (Sulmazol), a new cardiotonic agent, in coronary artery disease: improved ventricular wall motion, increased pump function and abolition of pacing-induced ischemia.

Authors:  J Thormann; M Schlepper; W Kramer; M Gottwik; M Kindler
Journal:  J Am Coll Cardiol       Date:  1983-08       Impact factor: 24.094

5.  Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside.

Authors:  B E Jaski; M A Fifer; R F Wright; E Braunwald; W S Colucci
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

6.  Physiologic assessment of the inotropic, vasodilator and afterload reducing effects of milrinone in subjects without cardiac disease.

Authors:  K M Borow; P C Come; A Neumann; D S Baim; E Braunwald; W Grossman
Journal:  Am J Cardiol       Date:  1985-04-15       Impact factor: 2.778

7.  Effects of KB-944, a novel calcium antagonist, in several models of canine myocardial ischemia.

Authors:  L R Pelc; G J Gross; D C Warltier
Journal:  J Pharmacol Exp Ther       Date:  1986-07       Impact factor: 4.030

8.  Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone.

Authors:  E S Monrad; R G McKay; D S Baim; W S Colucci; M A Fifer; G V Heller; H D Royal; W Grossman
Journal:  Circulation       Date:  1984-12       Impact factor: 29.690

9.  Cardiovascular profile of pimobendan, a benzimidazole-pyridazinone derivative with vasodilating and inotropic properties.

Authors:  P D Verdouw; J M Hartog; D J Duncker; W Roth; P R Saxena
Journal:  Eur J Pharmacol       Date:  1986-07-15       Impact factor: 4.432

10.  Central and regional vascular hemodynamics following intravenous milrinone in the conscious rat: comparison with dobutamine.

Authors:  H Drexler; S Höing; F Faude; H Wollschläger; H Just
Journal:  J Cardiovasc Pharmacol       Date:  1987-05       Impact factor: 3.105

View more
  22 in total

1.  Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression.

Authors:  Andrea Morelli; Stefano De Castro; Jean-Louis Teboul; Mervyn Singer; Monica Rocco; Giorgio Conti; Leonardo De Luca; Emanuele Di Angelantonio; Alessandra Orecchioni; Natesa G Pandian; Paolo Pietropaoli
Journal:  Intensive Care Med       Date:  2005-04-06       Impact factor: 17.440

Review 2.  [Role of Levosimendan in intensive care treatment of myocardial insufficiency].

Authors:  S Rehberg; C Ertmer; H Van Aken; M Lange; K Bröking; A Morelli; M Westphal
Journal:  Anaesthesist       Date:  2007-01       Impact factor: 1.041

3.  [Pilot study of levosimendan : Effect on liver blood flow and liver function in acute decompensated heart failure].

Authors:  K Lenz; A Gegenhuber; F Firlinger; G Lohr; P Piringer
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-04-19       Impact factor: 0.840

4.  Effects of levosimendan/furosemide infusion on plasma brain natriuretic peptide, echocardiographic parameters and cardiac output in end-stage heart failure patients.

Authors:  Mauro Feola; Enrico Lombardo; Camillo Taglieri; Paola Vallauri; Salvatore Piccolo; Roberto Valle
Journal:  Med Sci Monit       Date:  2011-02-25

5.  Beneficial impact of levosimendan in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials.

Authors:  Tiziana Bove; Andrea Matteazzi; Alessandro Belletti; Gianluca Paternoster; Omar Saleh; Daiana Taddeo; Roberto Dossi; Teresa Greco; Nikola Bradic; Ino Husedzinovic; Caetano Nigro Neto; Vladimir V Lomivorotov; Maria Grazia Calabrò
Journal:  Heart Lung Vessel       Date:  2015

6.  Effects of Single Drug and Combined Short-term Administration of Sildenafil, Pimobendan, and Nicorandil on Right Ventricular Function in Rats With Monocrotaline-induced Pulmonary Hypertension.

Authors:  Telma M Nakata; Ryou Tanaka; Rieko Yoshiyuki; Toshiharu Fukayama; Seijiro Goya; Ryuji Fukushima
Journal:  J Cardiovasc Pharmacol       Date:  2015-06       Impact factor: 3.105

7.  Levosimendan attenuates multiple organ injury and improves survival in peritonitis-induced septic shock: studies in a rat model.

Authors:  Cheng-Ming Tsao; Kai-Yi Li; Shiu-Jen Chen; Shuk-Man Ka; Wen-Jinn Liaw; Hsieh-Chou Huang; Chin-Chen Wu
Journal:  Crit Care       Date:  2014-11-29       Impact factor: 9.097

8.  Levosimendan: a cardiovascular drug to prevent liver ischemia-reperfusion injury?

Authors:  Peter Onody; Rita Stangl; Andras Fulop; Oliver Rosero; David Garbaisz; Zsolt Turoczi; Gabor Lotz; Zoltan Rakonczay; Zsolt Balla; Viktor Hegedus; Laszlo Harsanyi; Attila Szijarto
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

Review 9.  Levosimendan in critical illness: a literature review.

Authors:  Charalampos Pierrakos; Dimitrios Velissaris; Federico Franchi; Luigi Muzzi; Menelaos Karanikolas; Sabino Scolletta
Journal:  J Clin Med Res       Date:  2014-02-06

Review 10.  Renal effects of levosimendan: a consensus report.

Authors:  Mehmet B Yilmaz; Elena Grossini; José C Silva Cardoso; István Édes; Francesco Fedele; Piero Pollesello; Matti Kivikko; Veli-Pekka Harjola; Julia Hasslacher; Alexandre Mebazaa; Andrea Morelli; Jos le Noble; Anders Oldner; Ignacio Oulego Erroz; John T Parissis; Alexander Parkhomenko; Gerhard Poelzl; Sebastian Rehberg; Sven-Erik Ricksten; Luís M Rodríguez Fernández; Markku Salmenperä; Mervyn Singer; Sascha Treskatsch; Bojan Vrtovec; Gerhard Wikström
Journal:  Cardiovasc Drugs Ther       Date:  2013-12       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.